Heart-Shield drugs tested for cancer patients
NCT ID NCT06844669
Summary
This study tests whether two common heart medications can prevent heart damage in breast cancer patients receiving targeted therapy. Researchers want to see if giving carvedilol (a beta blocker) and/or empagliflozin (an SGLT2 inhibitor) alongside cancer treatment is safe and feasible. The goal is to protect patients' hearts so they can complete their cancer treatment without interruptions.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.